# Nephrotic Syndrome Due to Sunitinib: A Rare Complication of Treatment of Renal Cell Carcinoma

## TL;DR

A 62-year-old man with kidney cancer developed a rare kidney condition called nephrotic syndrome while on sunitinib treatment, which resolved after stopping the drug.

## Contribution

This case report highlights sunitinib-induced nephrotic syndrome as a rare but manageable complication in renal cell carcinoma treatment.

## Key findings

- The patient developed nephrotic syndrome during sunitinib therapy for renal cell carcinoma.
- Discontinuation of sunitinib led to resolution of nephrotic syndrome.
- A multidisciplinary approach was crucial for managing the patient's complex medical condition.

## Abstract

This case report details a 62-year-old male with a history of right renal cell carcinoma (RCC) who developed sunitinib-induced nephrotic syndrome during treatment. The patient had a complex medical history, including a right nephrectomy in 2009, brain metastasis excisions in 2011 and 2012, and prolonged sunitinib therapy. Hypothyroidism, hypertension, and various surgeries further complicated his clinical picture. In April 2022, the patient presented with bilateral pedal edema, acute kidney injury superimposed on chronic kidney disease, and proteinuria. Upon examination, the decision was made to discontinue sunitinib, leading to the resolution of nephrotic syndrome. Adjustments in thyroxine dosage were made, and pharmacological interventions were employed to manage proteinuria and renal dysfunction. A multidisciplinary approach involving oncologists, nephrologists, and endocrinologists was essential in achieving a favorable outcome. The case highlights the intricate balance required in managing patients undergoing targeted cancer therapies, emphasizing the importance of vigilant monitoring, prompt intervention, and a collaborative approach for optimal patient care.